BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, April 29, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 2004

View Archived Issues

Antitumor effects of CpG-7909 in several types of human cancer

Read More

Synthetic Australian snake venom derivative effective for wound healing

Read More

Restoration of CFTR function with SV40 gene therapy

Read More

Antitumor effects and safety of rhLF in advanced cancer patients

Read More

Novel potent and selective 5-HT2C agonists for the treatment of obesity discovered at Wyeth

Read More

Study results on GLP-1 analogue CJC-1131 presented during ADA

Read More

Synergistic effects of IL-21 and rituximab in B-lymphoma cell lines

Read More

An EGF vaccine reported to improve survival in advanced lung cancer

Read More

Positive preliminary phase III results for Sativex in neuropathic pain

Read More

Crucell enters PER.C6 licensing agreement with Chiron

Read More

FDA accepts IND for stem cell mobilizing drug CTCE-0214

Read More

Sosei's phase I trial of SOU-001 cleared to begin in U.K.

Read More

First patient enrolled in phase I/II study of TheraCIM hR3 for pediatric glioma

Read More

ZYC-101a shows 100% efficacy in patients with high-grade cervical dysplasia

Read More

Pivotal phase III trial of Rencarex for renal cell carcinoma opens enrollment

Read More

Symadex enters phase I in patients with advanced solid tumors

Read More

SVT-40776 progresses into phase II for urinary incontinence

Read More

Daily Infergen plus ribavirin evaluated for HCV in new DIRECT trial

Read More

Ovation acquires Buronil from Lundbeck

Read More

IR-103 enters first clinical study for HIV

Read More

First phase IIa patients receive BrachySil for liver cancer

Read More

Two series of gamma-secretase inhibitors identified at Merck

Read More

AstraZeneca presents novel PTP-1B inhibitors

Read More

Boehringer Ingelheim scientists describe new ICAM-1/LFA-1 interaction inhibitors

Read More

Dual alpha7 nAChR agonists/5-HT3 antagonists for psychosis, cognition disorders, etc.

Read More

New antilipolytic agents targeting hRUP38 receptors

Read More

T-614 reported safe and effective in patients with active rheumatoid arthritis

Read More

Novel chemokine CCR1 antagonists and their use covered by Pfizer patent

Read More

New monoamine reuptake inhibitors developed at NeuroSearch

Read More

Preliminary data on the efficacy of epratuzumab in SLE

Read More

Clinical response found with eculizumab in rheumatoid arthritis

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 28, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 28, 2026
  • Silhouette of head, brain

    Plasticity, properly parsed, provides psychiatric platform

    BioWorld
    If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
  • Roche identifies new TREM2 agonists

    BioWorld Science
    F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
  • Three red darts on target

    Sun Pharma to acquire Merck spinoff Organon for $11.75B

    BioWorld
    Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing